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To the Editor:
Sheri et al. reported in the Annals of Surgical
Oncology on the signiﬁcance of isolated tumor cells
(ITC).
1 At the moment the subject of ITC or SUB-
micrometastases, minimal sentinel node (SN) tumor
burden is a hot issue. Therefore, it is very interesting
that the experience from the John Wayne Cancer
Institute (JWCI) has been reported. This recent
publication does raise a few questions with regard to
the different results acquired by the authors com-
pared with recent publications by others.
2,3
The ﬁrst point of note is that the experience from
the JWCI goes back to 1991; this is an advantage,
because this leads to a longer median follow-up
compared with other single-center studies.
2,3 How-
ever, at the same time, it means that patients from the
early days of SN staging have been included. This is
a drawback because the pathology protocol, which
nowadays includes bivalving through the hilum, more
step-sections, more immunostains, and smaller
intervals,
4,5 was less extensive in the early days of SN
staging. This may be reﬂected in the very low SN
positivity identiﬁcation rate of only 15%, compared
with many other studies, which report rates between
20% and 30%.
5,6
This is supported by the fact that the authors have
found additional positive nodes in the completion
lymph node dissection (CLND) in 6 of 52 patients
(12%) with ITC. An extensive ‘‘modern’’ pathology
protocol should probably have picked up larger
tumor lesions in the original SN. We wonder if the
authors have extended the workup of the SNs of
these six patients to meet the standard extensive
workup used nowadays?
The second point of note is the extremely good
survival of SN negative patients reported by the
authors of 94% at 5y ears. This is somewhat higher
than in most other series, including the MSLT-I
trial, which report rates of around 90%.
6,7 The
reason for this is that the SN negative patients had
a much smaller median Breslow thickness (1.2mm!)
compared with the MSLT-I trial (1.8mm) or other
series.
5,7
The authors report that even if ITC would have
implications, its occurrence is very low at only 4%.
However, shouldnt this rate be calculated as pro-
portion of all SN positive patients? This is 57/
214 = 27%, who could possibly not beneﬁt from
CLND in our experience.
We believe that isolated tumor cells are not
always important, as has recently been demonstrated
in a multicenter trial for the detection of isolated
tumor cells using polymerase chain reaction (PCR)
techniques. Scoggins et al. did not demonstrate
additional prognostic information beyond standard
hematoxylin-eosin (HE) staining of SNs.
8 Although
Scheri et al. demonstrate a decreased survival in
their group of patients with ITC deﬁned as
<0.2mm,
1 we believe that the prognosis of patients
with SUB-micrometastatic disease as deﬁned as
<0.1mm has no impact on overall survival. A
multicenter study conducted within the EORTC
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1547Melanoma Group and recently presented at ECCO
14 in Barcelona, showed that patients with <0.1mm
SUB-micrometastases had an excellent 5-year over-
all survival rate of 91%. The rate of additional non-
SN positivity in CLND was 3% (which is identical
to the false negative rate in the MSLT-1 trial).
9 We
have also addressed the limit of 0.2mm as deﬁnition
for SUB-microscopic disease. The overall survival
decreased slightly to 89% at 5y ears; however the
occurrence of CLND positivity increases signiﬁ-
cantly to 10%, which leads us to believe that mela-
noma and breast cancer have a different biology
and thus require different cut-off values for SUB-
micrometastases.
Whether the excellent survival of patients with
<0.1mm SUB-micrometastatic disease is achieved
because of or in spite of CLND remains to be seen
and is the subject of an EORTC Melanoma Group
registration study, the MINITUB, which shall be
activated within the next year. Perhaps the MSLT-II
trial will also answer the question of which group(s)
of SN patients may or may not beneﬁt from CLND.
Until more data are available, clinicians should
realize that advising removal of all regional nodes to
all of their patients might change with respect to
further insights in long-term behavior of SUB-
micrometastatic involvement of the SN.
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